MOR:XETRA-MorphoSys AG (EUR)

COMMON STOCK | Biotechnology | XETRA

Last Closing Price

EUR 33.13

Change

-1.51 (-4.36)%

Market Cap

EUR 1.22B

Volume

0.30M

Avg Analyst Target

EUR 63.44 (+91.50%)

Avg User Target

EUR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


MorphoSys AG (MOR) Stock Analysis:
Based on the MorphoSys AG stock forecasts from 7 analysts, the average analyst target price for MorphoSys AG is EUR 63.44 over the next 12 months. MorphoSys AG’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of MorphoSys AG is Slightly Bullish , which is based on 5 positive signals and 4 negative signals. At the last closing, MorphoSys AG’s stock price was EUR 33.13. MorphoSys AG’s stock price has changed by -2.05 % over the past week, -8.06 % over the past month and -64.67 % over the last year.

About

MorphoSys AG, together with its subsidiaries, discovers, develops and commercializes therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignan ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-03 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NOVA:XETRA Novo Nordisk A/S

N/A

EUR134.00B 24.98 2.26
AXP:XETRA Alexion Pharmaceuticals Inc

N/A

EUR34.24B 59.28 36.13
5CV:XETRA CureVac NV

+0.65 (+1.73%)

EUR7.72B N/A N/A
EX9:XETRA Exelixis Inc

-0.20 (-1.37%)

EUR4.74B 31.84 16.99
BBZA:XETRA BB Biotech AG

-1.35 (-1.83%)

EUR4.21B 5.19 N/A
BIO3:XETRA Biotest Aktiengesellschaft

+0.20 (+0.51%)

EUR1.63B N/A 111.12
BIO:XETRA Biotest Aktiengesellschaft

N/A

EUR1.63B N/A 111.12
GBY:XETRA Sangamo Therapeutics Inc

+0.11 (+1.55%)

EUR1.03B N/A N/A
2EM:XETRA Ergomed plc

N/A

EUR0.75B 55.91 35.33
FYB:XETRA Formycon AG

+1.55 (+3.53%)

EUR0.50B N/A N/A

ETFs Containing MOR

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -64.69% 12% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -64.69% 12% F 1% F
Trailing 12 Months  
Capital Gain -64.67% 12% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -64.67% 12% F 1% F
Trailing 5 Years  
Capital Gain -19.52% 55% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.52% 55% F 12% F
Average Annual (5 Year Horizon)  
Capital Gain 8.93% 59% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.93% 59% F 58% F
Risk Return Profile  
Volatility (Standard Deviation) 36.16% 35% F 19% F
Risk Adjusted Return 24.69% 59% F 34% F
Market Capitalization 1.22B 72% C- 69% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 23.61 71% C- 48% F
Price/Book Ratio 2.05 72% C- 57% F
Price / Cash Flow Ratio 34.73 17% F 12% F
EV/EBITDA 12.24 88% B+ 45% F
Management Effectiveness  
Return on Equity -25.10% 56% F 11% F
Return on Invested Capital 14.48% 89% B+ 83% B
Return on Assets -6.95% 61% D- 7% F
Debt to Equity Ratio 43.90% 43% F 55% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.79 65% D 79% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.